Business Wire

Alpega Announces the 14th Edition of Connecta: One of Europe’s Largest Logistics Networking Event

Share

Alpega is excited to announce the return of Connecta, the premier networking event in the European road transport sector, celebrating its 14th edition. Scheduled for October 10th and 11th, 2024, at the prestigious Marriott Auditorium Conference Center in Madrid, this year's event promises to be the most comprehensive and impactful yet.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716487251/en/

(Photo: Business Wire)

Unparalleled Networking Opportunities

With over 500 professionals from across Europe expected to attend, Connecta 2024 will offer unmatched networking opportunities. Participants can generate significant business prospects within a single day, thanks to a meticulously planned agenda of networking activities. This event brings together the major players in the market, offering attendees a unique platform to engage in meaningful conversations and forge valuable connections.

A Full Logistics Network Representation

For the first time, Connecta 2024 will feature all logistics network participants, including carriers, freight forwarders, and shippers. This comprehensive representation ensures a holistic view of the industry, facilitating deeper insights and collaboration across different segments of the transport sector.

Showcasing the Latest Innovations

Connecta 2024 will also be a platform to showcase the latest innovations in the logistics sector. Attendees will have the opportunity to explore cutting-edge solutions and technologies that are transforming the industry, providing valuable insights into future trends and advancements.

Expanded Agenda with Key Panels and Workshops

The 2024 edition of Connecta boasts an expanded agenda, beginning on Thursday afternoon with a series of key panels and workshops. We are excited to confirm an inaugural session with Boston Consulting Group (BCG), led by Jesus Montero, Lead Knowledge Analyst in Logistics, presenting insightful analysis on industry trends alongside major sector players. Additionally, attendees can look forward to a networking workshop led by the renowned Jose Maria Salles, providing practical tools and strategies for effective networking.

Why Attend Connecta 2024?

“Connecta is more than just a networking event; it's a pivotal moment for the European logistics community to come together, share insights, and drive innovation. This year's edition will be our most impactful yet, offering unparalleled opportunities to connect, learn, and grow,” said Todd DeLaughter, CEO of Alpega.

  • Engage with Industry Leaders: Meet and converse with top influencers and decision-makers in the European road transport industry.
  • Generate Business Opportunities: Utilize tailored networking activities to create valuable business prospects in a single day.
  • Gain Industry Insights: Attend sessions and panels led by industry experts, including a detailed analysis of current trends by BCG.
  • Comprehensive Network Representation: Benefit from the presence of carriers, logistics operators, and shippers, offering a complete view of the transport chain.
  • Discover Innovations: Explore the latest technologies and solutions shaping the future of logistics.

Don’t miss this unparalleled opportunity to connect, learn, and grow within the European road transport sector. Join us at Connecta 2024 and be part of the conversation shaping the future of the industry.

Registration and Additional Information
For more details and to register for Connecta 2024, please visit our official website Alpega Connecta. Special early bird prices are available until July 31st.

About Alpega

Alpega is a global leader in logistics SaaS software, dedicated to delivering comprehensive end-to-end solutions for all transport requirements. Our mission is to empower shippers, forwarders, and carriers through efficient digitalization, addressing today’s logistics challenges and driving smarter logistics for a greener tomorrow.

Leveraging extensive carrier-based assets, Alpega provides tangible benefits in Transport Execution, Freight Planning, Freight Sourcing and Payment, Dock Scheduling, and Data Insights. As the only SaaS provider offering Transport Management Systems (TMS) for shippers, and with an 80,000-strong open carrier network that covers about 10% of all commercial trucks in Europe, we lead in innovation and efficiency.

Our connectivity extends through three premier freight exchanges in Europe, with notable leadership in Iberia, Romania, Central, and Southeastern European regions, facilitating seamless matching of freight loads with transportation capacity.

With over three decades of transportation expertise, we help businesses streamline their supply chain planning and execution, reducing costs and increasing visibility. Our community of 80,000 carriers and 200,000 members is seamlessly connected daily, efficiently managing vital transport operations. This network harnesses the power of collective intelligence, driving data-driven insights and optimizations across the logistics ecosystem, and creating a network effect that adds significant value for our customers. Operating in 80 countries, Alpega boasts a diverse team of over 450+ professionals representing 31 nationalities.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240716487251/en/

Contacts

Media:
Olga Álvarez
Community and Events Team Lead
olga.alvarez@alpegagroup.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press Release

Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable

GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press Release

Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus

Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press Release

Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye